en · de · es · fr · pt
sr9009-notes.peptides6155.com › Faq › Background And Mechanism — Questions and Answers

Background And Mechanism — Questions and Answers

By Editorial Desk · published 2025-08-29 · last reviewed 2025-09-12 · Faq

This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Regulation, Testing, and Storage

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Related pages on this site

Handling, Analysis, and Regulation

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Reference notes

The Platform 2 VTOL drones, launched in April 2025, are suited for shorter range home deliveries. They take off and land vertically, are capable of fixed-wing flight at up to 110 kilometres per hour (70 mph), and hover at an altitude of 100 metres (330 ft) to slowly lower packages on a wire. Packages are lowered in a delivery "droid" that uses sensors and propellers to deliver the package within a 1 metre (3.3 ft) diameter. The drones can carry up to 8 pounds (3.6 kg) of cargo within a 10 mi (16 km) radius, are capable of a more precise delivery than its previous generation, and can recharge autonomously.

which can be further processed to calculate the enthalpy of metal-ligand interaction. Although this example is between a metal and a ligand, it is applicable to any ITC experiment, regarding binding interactions. As a part of the analysis, a number of protons are required to calculate the solvent-independent thermodynamics. This can be easily done by plotting a graph such as shown below.

== History == Cold hemagglutination was first reported by Landsteiner in 1903 and found to occur in human beings in 1918. The association of cold hemagglutination with hemolysis was described in 1937 by Rosenthal and Corten. During the 1960s, Dacie and Schubothe published systematic descriptions of 16 CAD patients each. The auto antibodies responsible for hemagglutination at low temperatures, cold agglutinins (CA), may be found in the sera of healthy subjects as well as in patients with AIHA of the cold reactive types. CA bind to erythrocyte surface antigens at a temperature optimum of 0–4 °C. In contrast to polyclonal CA in healthy individuals, monoclonal CA often have a high-thermal amplitude, which contributes to their pathogenicity at temperatures approaching 37 °C. Binding of CA causes agglutination of erythrocytes and the antigen–antibody complex induces complement (C) activation and hemolysis. Essential clinical manifestations of primary CAD are hemolytic anemia and cold-induced circulatory symptoms. Exact estimates of the severity of anemia and the frequency of cold-induced symptoms, however, have not been provided until recent years.

Sources: en.wikipedia.org

Notes from published material

As such, the yeasts involved in what has been typically called top-cropping or top-fermenting ale may be both Saccharomyces cerevisiae and complex hybrids of Saccharomyces cerevisiae and Saccharomyces kudriavzevii. Three notable ales, Chimay, Orval and Westmalle, are fermented with these hybrid strains, which are identical to wine yeasts from Switzerland.

In popular culture, the Bro Code is a friendship etiquette to be followed among men or, more specifically, among members of the bro subculture. The notion of an unwritten set of rules that govern the relationship between straight male friends is present in modern American popular culture at least since 1991. In the Seinfeld episode "The Stranded", which aired on November 27 that year, Jerry Seinfeld says the following monologue, in one of his stand-up bits:

In statistical copolymers the sequence of monomer residues follows a statistical rule. If the probability of finding a given type monomer residue at a particular point in the chain is equal to the mole fraction of that monomer residue in the chain, then the polymer may be referred to as a truly random copolymer (structure 3). Statistical copolymers are dictated by the reaction kinetics of the two chemically distinct monomer reactants, and are commonly referred to interchangeably as "random" in the polymer literature. As with other types of copolymers, random copolymers can have interesting and commercially desirable properties that blend those of the individual homopolymers. Examples of commercially relevant random copolymers include rubbers made from styrene-butadiene copolymers and resins from styrene-acrylic or methacrylic acid derivatives. Copolymerization is particularly useful in tuning the glass transition temperature, which is important in the operating conditions of polymers; it is assumed that each monomer occupies the same amount of free volume whether it is in a copolymer or homopolymer, so the glass transition temperature (Tg) falls between the values for each homopolymer and is dictated by the mole or mass fraction of each component. A number of parameters are relevant in the composition of the polymer product; namely, one must consider the reactivity ratio of each component. Reactivity ratios describe whether the monomer reacts preferentially with a segment of the same type or of the other type.

Electronic cigarette aerosol contains fine and ultrafine particles of particulate matter, including particulate matter 2.5 μm or smaller in diameter (PM2.5). Studies have found that electronic cigarette aerosol can raise PM2.5 concentrations to several hundred micrograms per cubic meter (μg/m³), with measurements of 600–800 μg/m³ in vape shops and conventions and peak values exceeding 1,000 μg/m³; these levels are far above typical indoor backgrounds (8–52 μg/m³) and greatly exceed the World Health Organization’s 24‑hour PM2.5 guideline of 25 μg/m³ for outdoor air. PM2.5 is capable of penetrating deep into the lungs and entering the bloodstream, where it is associated with severe systemic inflammation, cardiovascular disease, and premature death.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

Network